Your session is about to expire
← Back to Search
Vasoactive Intestinal Peptide (VIP) Analog
Treatment for COVID-19 (SAMICARE Trial)
N/A
Waitlist Available
Research Sponsored by NeuroRx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Critical COVID-19 with Respiratory Failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in NCT04311697, who live more than 50 miles from an existing collaborating research center, or who are already hospitalized and cannot safely be transferred to a collaborating research facility may be considered for expanded access by the sponsor. Treating physicians must complete FDA Form 3396 and receive a letter of authorization from NeuroRx, along with local IRB authorization. Please refer to FDA guidance for Individual Patient Expanded Access https://www.fda.gov/media/91160/download
Eligible Conditions
- COVID-19
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
NeuroRx, Inc.Lead Sponsor
12 Previous Clinical Trials
1,159 Total Patients Enrolled
5 Trials studying COVID-19
820 Patients Enrolled for COVID-19
Clinigen, Inc.Industry Sponsor
9 Previous Clinical Trials
357 Total Patients Enrolled
Nephron Pharmaceuticals, Inc.UNKNOWN
Share this study with friends
Copy Link
Messenger